Tigecycline's Volume of Distribution
Tigecycline has a large volume of distribution (Vd) of about 7-10 L/kg, meaning it distributes extensively into tissues beyond the plasma volume.[1][2] This high Vd reflects its lipophilic structure, allowing penetration into fat, skin, lungs, and intracellular sites where many Gram-negative and Gram-positive pathogens reside.
Impact on Dosing for Tissue Infections
High Vd supports tigecycline's use in skin/soft tissue infections (SSTIs), intra-abdominal infections (IAIs), and complicated pneumonia, as tissue concentrations exceed plasma levels by 2-7 times.[1][3] Standard dosing (100 mg load, then 50 mg IV every 12 hours) achieves effective site-specific exposure without frequent adjustments for body weight in most adults. For obese patients (>100 kg), clinicians often increase to 75-100 mg every 12 hours to account for expanded tissue volume, maintaining free drug levels above MICs.[4]
Limitations in Bloodstream Infections
Large Vd results in low plasma concentrations (peak ~0.6 mcg/mL post-50 mg dose), limiting efficacy against bacteremia or endocarditis where high serum levels are needed.[2][5] Guidelines (IDSA) advise against tigecycline for bloodstream infections due to subtherapeutic plasma exposure and higher mortality risk versus comparators like carbapenems.[6]
Considerations for Special Populations
- Obesity: Vd scales with fat mass, so higher doses prevent underdosing; monitor for nausea, the primary side effect amplified by elevated exposure.[4]
- Critically Ill/Hypoalbuminemia: Reduced protein binding (up to 80% unbound) increases free fraction, but expanded Vd from fluid shifts may require TDM or higher dosing.[3]
- Renal/Hepatic Impairment: No adjustment needed as clearance is fecal/biliary, not renal; Vd remains stable.[1]
How to Adjust Treatment Plans
Select tigecycline for deep-seated infections (e.g., abscesses) where tissue penetration matters, but pair with agents like beta-lactams for bloodstream involvement. Therapeutic drug monitoring isn't routine but helps in obesity or sepsis. Avoid monotherapy in high-inoculum infections due to bacteriostatic action compounded by low plasma levels.[5][6]
Sources
[1]: Tigecycline Package Insert (FDA)
[2]: DrugPatentWatch.com - Tigecycline Pharmacokinetics
[3]: Muralidharan et al., Antimicrob Agents Chemother (2005)
[4]: IDSA Guidelines on SSTIs (2014)
[5]: Tasina et al., Clin Microbiol Infect (2011)
[6]: IDSA/ATS Community-Acquired Pneumonia Guidelines (2019)